NEWS COMMENTARY

Bayer expands its collaboration with skin microbiome startup Azitra by leading its $17 million Series B round

Published:
October 26, 2020
Coverage:
Emerging Ecosystems in Agrifood and Health
Activities:
Investment More...
Average importance

This investment round builds off Bayer's previous joint development agreement and includes other existing investors like Bios Partners and Connecticut Innovations, bringing Azitra's funding to $41 million. This influx of cash will help Azitra scale its skin microbiome modulation platform for skin conditions like acne and atopic dermatitis, focused on both consumer health and clinical applications. Azitra develops live biotherapeutic products (LBPs) based on Staphylococcus epidermidis bacterial strains for skin microbiome modulation. LBP-containing skin microbiome products are currently limited on the market. This partnership will give Bayer a head start in the space as it looks to commercialize LBPs for consumer health applications.

For the original news article, click here .


Further Reading

Brightseed raises $27 million for its functional ingredient discovery platform

News Commentary | September 21, 2020

This brings the company's funding to $52 million. Brightseed intends to use at least part of the funding for completion of clinical trials. The trials are intended to validate the health claims of the ingredients, the first one addressing metabolic health, that the company discovers and ... Not part of subscription

Evolve BioSystems raises $55 million to expand its probiotics for infant health application

News Commentary | February 12, 2021

This Series D funding round was led by Cargill and Manna Tree and will help Evolve expand the market reach of its probiotic supplement targeting infant health. This investment also signals Cargill's sustained interest in the microbiome space, coming on the heels of its previous investment in ... Not part of subscription

DSM invests $100 million into launch of personalized nutrition company Hologram Sciences

News Commentary | April 07, 2021

This builds off DSM's series of previous moves in the personalized nutrition space, much of which occurred in 2018 and 2019. It appears the company will provide diagnostics, automated and dietitian‑based recommendations, and personalized supplements, with current focus areas of immune, gut, and ... Not part of subscription